The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
0.025% of shares sold yet price falls 2.5%. Typical AIM.
Shall top up if this drops between 7 - 8p
Posting for anyone interested, the Stroke Association Manifesto from last month.
If nothing else it’s worth reading the foreword and then letting the reality of what Upfront might have set in.
https://www.stroke.org.uk/get-involved/campaigns/election/General%20Election%20Manifesto%20-%20Stroke%20Association.pdf
Not a suckers share, just an undervalued one presenting a great opportunity for those willing and capable of using their own brain instead of an artificial one.
Pleased with 90% decline in share price since floating?
Ai search on this com says it's a 'suckers' share.
DYOR
It all smacks of careful forward, visionary planning. They are "pleased" and so should we be.
Mustn’t Have parted on good terms no notice period there gone ,thinks there’s a story to be had as to why immediate replacement.
Walbrook are ABDX's investor relations company not Nomad and remain so as far as I can see.
WH Ireland have replaced Singer capital as sole broker/Nomad.
I agree. Walbrook were hopeless as evidenced with Omega Diagnostics handling during Covid. Never trusted them, and pleased to see them out.
Usually when they are looking to raise capital.
I am in the same boat with not understanding why small companies like ABDX go through this exercise, however I tend not to believe in co-incidences so this following on from the acquisition yesterday, suggests to me that this is part of a likely expansion plan.
I think this much more likely to be a positive than a neutral act. (imo dyor etc)
I guess there must be a perceived advantage over the previous ones. But that may be simply the opinion of the BOD, or personal contact . . . etc, possibly an issue with the previous ones . . .
If I had to guess, and given ABDX'x tendency towards tight lipped, strategic planning . . . I would suggest that the BOD perceive the new broker to be more suited, better networked etc for the next phase of ABDX's development.
They wouldn't change for no reason. Perhaps it will become clear in time.
Sorry if that is a bit waffly, I am clutching at straws.
Me neither. Do you know why companies change Nomad/Broker?
TBH, I am not really in a position to judge the pros and cons of different brokers. Anyone any views on these new guys?
I agree we all own a little bit less of ABDX as a result of the issue. But we didn't issue at a discount and so assuming the price we paid is correct, we all own a little bit less of a company that is now worth a little bit more.
The fact IVDeology is currently loss making is neither here nor there.
Our shareholdings have been diluted. Our value has not.
By most metrics issuing shares to purchase a loss making company is dilutive.
Hi Peter
What I was trying to say was that our value hasn't been diluted, assuming the valuation is correct.
Had we raised to acquire in cash, at an inevitable discount given current capital markets, then more shares would have been issued to obtain the same value.
This deal hasn't encouraged share buying (or selling) at the moment. Surely, in the scheme of things ABDX is grossly undervalued??
Still holding firm, and with plenty of hope for the near future.
Chard_Nick
Hi Muck165
I'm just asking this out of interest. When you said "Initial thoughts are; -Non dilutive acquisition". I wondered if that was right. If Abingdon are issuing 5 million shares to cover this, does that not dilute our investment? If it helps the company to generate more business then the investment should pay us back in a year or two so we shouldn't lose out as such.
Just seeking clarification.
Another couple of thoughts…
ABDX must see reg support as a growth area, and I wonder if this stems from being unable to cope with all work opportunities in house given current resource.
We’ve waived up to £500k in fees re the FOFH deal, and have now made an acquisition. Doesn’t suggest Yates has concerns about H2 revenue or cash position. Remember, at the investor presentation he was clear H2 this year will beat H2 last year (£2.9m), and in fact they are aiming for a material increase.
Yep. It strengthens our full service offering in an area all developers must go through but few understand or, I suspect, have the aptitude or desire to do themselves. And as is pointed out in the RNS, the whole reg environment here and in the US is going through significant overhaul at the mo.
Good assessment there Muck. Here, here.
Onwards and upwards.
Initial thoughts are;
-Non dilutive acquisition
-Little integration friction given current owners will continue to run it as a subsid, and because of its small size and employee base (2 employees recorded in last years accounts).
-Bolsters our regulatory support and provides us with a U.K. Responsible Person
-No impact on cash.
- Wouldn’t sell for ABDX paper unless they had confidence in ABDX growth
- U.K. market is often first in commercial roll out because UKCA seems less difficult to get, which is attractive to non U.K. and particularly US developers (who also need a U.K. responsible person). Boosting expertise should therefore help with international customer base and pipeline opportunities.
- Should wipe its face based on current revenues, but would expect workloads/revenue to increase through ABDX customers, contacts and pipeline.
I think this is a great acquisition.
Thanks Muck,
Looks some very good tests to tempt the retail market to save the time and stress of dealing with Dr's, esp on the big ones like Bowl and prostate cancer.
Perhaps just a little observation, but we know Salignostics have been progressing FDA approval for Salistick for nearly three years now, that they are currently "positioning" the product in the States, and that Salistick made Time Magazine's top 200 inventions of 2023.
Well today Time published its top 100 most influential people in Health and included Raluca Cohen, one of the scientist behind Salistick, in this list.
Can't hurt in the US positioning....
https://time.com/collection/time100-health/
https://time.com/6962679/raluca-cohen/